WO1996004261A1 - Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes - Google Patents

Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes Download PDF

Info

Publication number
WO1996004261A1
WO1996004261A1 PCT/GB1995/001323 GB9501323W WO9604261A1 WO 1996004261 A1 WO1996004261 A1 WO 1996004261A1 GB 9501323 W GB9501323 W GB 9501323W WO 9604261 A1 WO9604261 A1 WO 9604261A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
formula
compound
pharmaceutically acceptable
benzoxazolyl
ml
Prior art date
Application number
PCT/GB1995/001323
Other languages
French (fr)
Inventor
David Haigh
Harshad Kantilal Rami
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with heteroatoms or with carbon atoms having three bonds to hetero atoms, with at the most one to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2

Abstract

A compound of formula (I): or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein Ro represents 2-benzoxazolyl or 2-pyridyl and R1 represents CH¿2?OCH3 or CF3; a process for the preparation of such compounds, a pharmaceutical composition containing such compounds and the use of such compounds and compositions in medicine.

Description

BENZOXAZOLES AND PRYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF THE TYPE I I DIABETES

This invention relates to certain novel compounds, to a process for preparing such compounds, to pharmaceutical compositions containing such compounds and to 5 the use of such compounds and compositions in medicine.

International Patent Application, Publication Number WO 94/01420 discloses compounds of formula (A):

A 1 '-X'-(CH2)n-O-A2'- A3'- Y.R2' (A)

10 or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein:

A 1 represents a substituted or unsubstituted aromatic heterocyclyl group;

A2' represents a benzene ring having three optional subsrituents;

15 A3' represents a moiety of formula -(CH2)m-CH(OR^ )- wherein R1' represents substituted or unsubstituted alkyl, aryl, aralkyl or alkylcarbonyl and m represents an integer in the range of from 1 to 5, or A3' represents a moiety of formula -(CH2)m'-l- CH=C(0R1')- wherein R1' and m' are as defined above; R2' represents OR3' wherein R3' represents hydrogen, alkyl, aryl or aralkyl or R2'

20 represents an aromatic heterocyclyl group or -NR^ R^' wherein R^' and R^' each independently represent hydrogen, alkyl or alkylcarbonyl or R^' and R^' together with the nitrogen atom to which they are attached form a heterocyclic ring, providing that R2 represents an aromatic heterocyclyl group only when Y' as defined below represents a bond ;

25 X' represents NR' wherein R' represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group;

Y' represents C=O or C=S or a bond providing that Y' represents a bond only when R2' represents the above mentioned aromatic heterocyclyl group; and

30 n' represents an integer in the range of from 2 to 6.

These compounds are stated to have inter alia good blood-glucose lowering activity and are therefore of potential use in the treatment and/or prophylaxis of hyperglycaemia and to be of particular use in the treatment of Type II diabetes.

It has now surprisingly been discovered that a particular group of compounds

35 falling within the generic scope of the compounds of formula (A) have particularly good blood-glucose lowering activity combined with freedom from adverse haematological and cardiac effects. These compounds are therefore considered to hold potential to be of particular use in the treatment and/or prophylaxis of hyperglycaemia and to be of particular use in the treatment of Type II diabetes. These compounds are also indicated to be of potential use for the treatment and/or prophylaxis of other diseases including hyperlipidaemia and hypertension. They are also indicated to be of use in the treatment and/or prophylaxis of cardiovascular disease, especially atherosclerosis. In addition these compounds are considered to be useful for treating certain eating disorders, in particular the regulation of appetite and food intake in subjects suffering from disorders associated with under-eating, such as anorexia nervosa, and disorders associated with over¬ eating, such as obesity and anorexia bulimia.

These compounds are also indicated to be of of potential use in the treatment and/or prophylaxis of renal disease, especially renal disease associated with the development of Type II diabetes including diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis and end stage renal disease. The prophylactic action of an insulin sensitiser upon nephropathy is also indicative that an insulin sensitising agent can be expected to prevent, reverse, stabilise or retard the progression of microalbuminuria to albuminuria. This is because microalbuminuria is considered to be a predictor of future nephropathy, especially in patients with clinical evidence of pre-diabetic insulin resistance syndrome, alternatively referred to as Syndrome X.

Accordingly, the present invention provides a compound of formula (I):

Figure imgf000004_0001

or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein R° represents 2-benzoxazolyl or 2-pyridyl and R^ represents CH2OCH3 or CF3.

Preferably, R° represents 2-benzoxazolyl.

Suitably, R1 represents CH2OCH3.

Preferably, R^ represents CF3

As indicated above, a compound of formula (I), and the pharmaceutically acceptable salts thereof, may exist in one of several tautomeric forms, all of which are encompassed by the present invention as individual tautomeric forms or as mixtures thereof.

Suitable pharmaceutically acceptable salts include salts of carboxy groups and acid addition salts. Suitable pharmaceutically acceptable salts of carboxy groups include metal salts, such as for example aluminium, alkali metal salts such as lithium, sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with lower alkylamines such as triethylamine, hydroxy alkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)amine or tri-(2-hydroxyethyl)amine, cycloalkylamines such as bicyclohexylamine, or with procaine, dibenzylpiperidine, N-benzyl-β-phenethylamine, dehydroabietylamine, N,N'-bisdehydroabietylamine, glucamine, N-methylglucamine or bases of the pyridine type such as pyridine, collidine, quinine or quinoline.

Suitable acid addition salts include pharmaceutically acceptable inorganic salts such as the sulphate, nitrate, phosphate, borate, hydrochloride and hydrobromide and, where feasible, pharmaceutically acceptable organic acid addition salts such as acetate, tartrate, maleate, citrate, succinate, benzoate, ascorbate, methanesulphonate, α-keto glutarate and α-glycerophosphate.

Suitable pharmaceutically acceptable solvates include hydrates.

The salts and/or solvates of the compounds of formula (I) may be prepared and isolated according to conventional procedures, for example sodium salts may be prepared by using sodium methoxide in methanol.

In a further aspect the present invention also provides a process for the preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable hydrate thereof, which process comprises hydrolysing a compound of formula (II):

Figure imgf000005_0001

wherein R° and R* are as defined in relation to formula (I) and L* represents a hydrolysable group; and thereafter, if required, preparing a pharmaceutically acceptable salt of the compound of formula (I) and/or a pharmaceutically acceptable solvate thereof.

A suitable hydrolysable group L* is a group of formula (a) or an epimer thereof:

Figure imgf000005_0002

H (a)

A suitable hydrolysable group L* is an Evans chiral auxiliary, for example a group of formula (b) or an epimer thereof:

Figure imgf000006_0001

A suitable hydrolysable group L^ is a Ci.g alkoxy group. The hydrolysis of the compound of formula (II) is carried out using conditions appropriate for hydrolysing the particular group L* chosen, for example when L* is a group of formula (a) or a C g alkoxy group, the hydrolysis is suitably carried out under acidic conditions, for example using dilute sulphuric acid, conveniently in a water/dioxan mixture, for example a 1:1 mixture, at any temperature which provides a suitable rate of formation of the required product, generally at an elevated temperature, such as in the range of from 50°C to 120°C, for example 90°C; or when I_l is a group of formula (b) the hydrolysis is generally carried out using lithium hydroperoxide in an aqueous solvent, such as aqueous tetrahydrofuran, at any temperature which provides a suitable rate of formation of the required product, generally at a reduced temperature, such as in the range of from - 10°C to 0°C, for example 0°C. Alternatively, when L s a group of formula (b) the hydrolysis may be effected under basic conditions, using for example aqueous sodium hydroxide, in an appropriate solvent such as aqueous tetrahydrofuran usually at ambient temperature. A compound of formula (II), wherein l is a moiety of the above defined formula (a) or (b), may be prepared from a compound of formula (HI) :

Figure imgf000006_0002

wherein R° and R* are as defined in relation to formula (I) and L2 represents a leaving group; (i) for compounds of formula (II) wherein L s a moiety of the above defined formula (a), by reaction with (S)-phenylglycinol; or (ii) for compounds of formula (II) wherein L* is a moiety of the above defined formula (b), by reaction with (S)-4-benzyloxazolidin-2-one, preferably an activated form thereof; and thereafter separating the required isomer from the mixture of diastereoisomers produced.

A suitable leaving group L2 is a halogen atom, for example a chlorine atom. The reaction between the compounds of formula (HI) and (S)-phenylglycinol may be carried out under conventional amidation conditions, for example in an inert solvent such as dichloromethane at a temperature which provides a suitable rate of formation of the required product, suitably at ambient temperature and preferably in the presence of a base such as rriethylamine.

A suitable activated form of 5 -4-benzyloxazolidin-2-one is a salted form, for example an alkali metal salted form, preferably a lithium salt.

The activated form of S -4-benzyloxazolidin-2-one may be prepared by any appropiate conventional method. Thus when the activated form is a lithium salt, it may be prepared by treating S)-4-benzyloxazolidin-2-one with a source of lithium ions in the presence of a base, suitably provided by n-butyllithium, in an aprotic solvent such as tetrahydrofuran, usually at a low temperature, for example in the range of from -78° to 0°C.

The reaction between the compound of formula (III) and the activated form of ('S/)-4-benzyloxazolidin-2-one may be carried out in an aprotic solvent, such as tetrahydrofuran, at a temperature which provides a suitable rate of formation of the required product, conveniently by allowing the reaction mixture to slowly warm from -78° to 0°C.

Preferably, the activated form of S -4-benxyloxazolidin-2-one is prepared and then reacted in-situ with the compound of formula (1Η).

A compound of formula (IH) may be prepared by hydrolysing the carboxylic ester COOR2 of a compound of formula (IV):

Figure imgf000007_0001

wherein R° and R* are as defined in relation to formula (I) and R2 represents an alkyl group, and thereafter converting the carboxylic acid group so formed into a moiety CO.L2.

A suitable alkyl group R2 is a Ci .5 alkyl group, especially a methyl group. The hydrolysis of the carboxylic ester may be effected by use of any conventional hydrolysing agent, such as an alkaline metal hydroxide, for example sodium hydroxide.

The hydrolysis of the compound of formula (IV) may be carried out in any suitable solvent such as a methanol/water mixture, conveniently a 1 : 1 mixture, at a temperature which provides a suitable rate of formation of the required product, suitably at an elevated temperature and conveniently at the reflux temperature of the solvent. The conversion of the carboxylic acid group into the moiety CO.L2 may be carried out using any appropiate conventional procedure, depending upon the particular nature of the group L2 chosen, thus when L2 is a halogen a suitable procedure involves treatment of the carboxylic acid with an oxalyl halide, for example oxalyl chloride when L2 is chlorine.

The reaction conditions for the conversion of the carboxylic acid group into the moiety CO.L2 will be dictated by the particular nature of L2 and the source of L2 chosen, for example when L2 is halogen and the source of L2 is oxalyl chloride then the reaction may be carried out in an inert solvent such as dichloromethane or benzene at a temperature which provides a suitable rate of formation of the required product, suitably at ambient temperature or at an elevated temperature such as the reflux temperature of the solvent.

It will be appreciated that die preparation and separation of a compound of formula (II) wherein i is an epimer of the above defined moiety (a) or (b) and its subsequent hydrolysis to afford a compound of formula (I) can be achieved by employing analogous methods to those described above for the preparation, separation and hydrolysis of a compound of formula (II) wherein i represents the above defined moiety (a) or (b).

A compound of formula (II) wherein L* is a moiety of formula (b) may also be prepared by dehydroxylation of a compound of formula (V):

Figure imgf000008_0001

(V) wherein R° and R1 are as defined in relation to formula (I) and X is a moiety of the above defined formula (b).

The dehydroxylation of the compound of formula (V) is conveniently carried out by treatment with a trialkylsilane, for example triethylsilane, preferably in the presence of trifluoroacetic acid and conveniently using trifluoroacetic acid as solvent, at any temperature providing a suitable rate of formulation of the product, for example at a temperature in the range from 0°C to room temperature.

It will be appreciated that a compound of formula (II) wherein L is a moiety of formula (b) would also be obtained by dehydroxylation of a compound of formula

(V) in which the hydroxy bearing stereocentre is epimerised.

A compound of formula (V) may be prepared by reacting a compound of formula (VIA):

Figure imgf000009_0001
wherein R° is as defined in relation to formula (I), with a compound of formula (VLB):

R'CHjj

Figure imgf000009_0002

wherein R^ is as defined in relation to formula (I); and thereafter separating the required isomer from die mixture of diastereoisomers produced.

Suitably in the above mentioned reaction, the compound of formula (VLB) is in an activated form, which is preferably provided by treating the compound of formula (VIB) with an alkylboron triflate, for example dibutylboron triflate, preferably in the presence of an amine base such as triethylamine. The activated form of the compound of formula (VLB) may be prepared by the appropriate conventional method depending upon the specific nature of the activated form chosen, for example the compound of formula (VIB) is reacted with dibutylboron triflate and triethylamine in an inert solvent such as dichloromethane at a temperature in the range of from -78° to 0°C. The reaction between the compounds of formulae (VIA) and (VIB) may be carried out in an in an inert solvent such as dichloromethane, at a temperature which provides a suitable rate of formation of the required product, conveniently by allowing the reaction mixture to slowly warm from -78° to 0°C.

Preferably, the activated form of the compound of formula (VIB) is prepared and then reacted in-situ with the compound of formula (VIA).

For compounds of formula (I) wherein R° represents 2-benzoxazolyl, a suitable compound of formula (VIA) is 4-[2-[N-(2-benzoxazolyl)-N- methylamino]ethoxy]benzaldehyde.

A suitable means for separating any required single isomer from a mixture of diastereoisomers is chromatography, such as preparative high pressure liquid chromatography or silica gel column chromatography. One convenient method for preparing a compound of formula (H) wherein L* is a C ι„6 alkoxy group is the basic alcoholysis of a compound of formula (II) wherein L.1 is a moiety of formula (b).

A suitable base is an alkali metal alkoxide, for example when L* is methoxy the compound of formula (II) wherein L* is moiety (b) is treated with sodium methoxide in methanol.

A compound of formula (I) may also be prepared by resolving a racemic compound of formula (VII):

Figure imgf000010_0001
wherein R° and R1 are as defined in relation to formula (I).

The resolution of a compound of formula (VII) may be carried out using known resolution procedures, for example by reacting the compound of formula (VII) with a resolving agent, such as an optically active acid or base, to provide a mixture of diastereoisomeric salts which may then be separated by fractional crystallisation and thereafter the compound of formula (I) may be regenerated from the separated diastereoisomer salt by conventional means, such as hydrolysis.

It will be appreciated that the compounds of formula (VII) comprise the compounds of formula (I) admixed with other optical isomers. A compound of formula (VH) or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, forms a further aspect of the present invention. The separated isomers of the compounds of formula (VII), in addition to the compounds of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, also comprise the present invention. Suitable acids or bases for resolving the compounds of formula (VII) are as described in Enantiomers, Racemates and Resolution, J Jaques et al. 1981, Wiley Interscience, especially at pages 255 and 256. Suitable methods for effecting the resolution are also disclosed by Jaques et al.

The compounds of formula (IV) and (VIA), for example 4-[2-[N-(2- benzoxazolyl)-N-methylamino]ethoxy]benzaldehyde, are known compounds or they may be prepared using methods analogous to those used to prepare known compounds, for example those disclosed in International Patent Application, Publication Number WO94/01420.

The compounds of formula (VIB) are known compounds or they may be prepared using methods analogous to those used to prepare known compounds, for example those disclosed in Organic Synthesis Vol. 68, p83, 1990 Ed. J.D. White or methods analogous thereto, in combination with conventional methodology for the preparation of acid chlorides.

It will be appreciated that in any of the abovementioned reactions any reactive group in the substrate molecule may be protected, according to conventional chemical practice. Suitable protecting groups in any of the abovementioned reactions are those used conventionally in the art. The methods of formation and removal of such protecting groups are those conventional methods appropriate to the molecule being protected.

It will be appreciated that the above mentioned preparation of the compounds of formula (I), or a pharmaceutically acceptable salt thereof and or a pharmaceutically acceptable solvate thereof, is a stereoselective procedure and that the compound of formula (I) is a single stereoisomer. The present invention also includes a compound of formula (I) when present in admixture with less than 50% w/w of its racemic isomer, that is when it is greater than 50% optically pure, suitably 80-100% and preferably 90-100% pure, such as 90-95%, most preferably 95- 100%, for example 95%, 96%, 97%, 98%, 99% or 99.9% optically pure.

In one preferred aspect there is provided a compound of formula (I) or a pharmaceutically acceptable salt thereof and or a pharmaceutically acceptable solvate thereof, in optically pure form. The absolute stereochemistry of compounds may be determined using conventional methods, such as X-ray crystallography.

As mentioned above the compounds of the invention are indicated as having useful therapeutic properties: The present invention accordingly provides a compound of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use as an active therapeutic substance.

Thus the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use in the treatment of and/or prophylaxis of hyperglycaemia.

In a further aspect the present invention also provides a compound of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use in the treatment and/or prophylaxis of hyperlipidaemia.

As indicated hereinbefore the present invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof for use in the treatment of hypertension, cardiovascular disease and certain eating disorders.

Cardiovascular disease includes in particular atherosclerosis.

Certain eating disorders include in particular the regulation of appetite and food intake in subjects suffering from disorders associated with under-eating ,such as anorexia nervosa, and disorders associated with over-eating, such as obesity and anorexia bulimia.

A compound of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, may be administered pei _ or, preferably, as a pharmaceutical composition also comprising a pharmaceutically acceptable carrier.

Accordingly, the present invention also provides a pharmaceutical composition comprising a compound of the general formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier therefor.

As used herein the term 'pharmaceutically acceptable' embraces compounds, compositions and ingredients for both human and veterinary use: for example the term 'pharmaceutically acceptable salt' embraces a veterinarily acceptable salt.

The composition may, if desired, be in the form of a pack accompanied by written or printed instructions for use.

Usually the pharmaceutical compositions of the present invention will be adapted for oral administration, although compositions for administration by other routes, such as by injection and percutaneous absorption are also envisaged.

Particularly suitable compositions for oral administration are unit dosage forms such as tablets and capsules. Other fixed unit dosage forms, such as powders presented in sachets, may also be used.

In accordance with conventional pharmaceutical practice the carrier may comprise a diluent, filler, disintegrant, wetting agent, lubricant, colourant, flavourant or other conventional adjuvant. Typical carriers include, for example, microcrystalline cellulose, starch, sodium starch glycollate, polyvinylpyrrolidone, polyvinylpolypyrrolidone, magnesium stearate or sodium lauryl sulphate.

Most suitably the composition will be formulated in unit dose form. Such unit dose will normally contain an amount of the active ingredient in the range of from 0.1 to 1000 g, more usually 0.1 to 500 mg, and more especially 0.1 to 250 mg.

The present invention further provides a method for the treatment and/or prophylaxis of hyperglycaemia in a human or non-human mammal which comprises administering an effective, non- toxic, amount of a compound of the general formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof to a hyperglycaemic human or non-human mammal in need thereof.

The present invention further provides a med od for the treatment of hyperlipidaemia in a human or non-human mammal, which comprises administering an effective, non-toxic, amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, to a hyperlipidaemic human or non-human mammal in need thereof.

Conveniently, the active ingredient may be administered as a pharmaceutical composition hereinbefore defined, and this forms a particular aspect of the present invention.

In the treatment and/or prophylaxis of hyperglycaemic humans, and/or the treatment and/or prophylaxis of hyperlipidaemic human, the compound of the general formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, may be taken in doses, such as those described above, one to six times a day in a manner such that the total daily dose for a 70 kg adult will generally be in the range of from 0.1 to 6000 mg, and more usually about 1 to 1500 mg.

In the treatment and/or prophylaxis of hyperglycaemic non-human mammals, especially dogs, the active ingredient may be adminstered by mouth, usually once or twice a day and in an amount in the range of from about 0.025 mg/kg to 25 mg/kg, for example 0.1 mg/kg to 20 mg/kg. Similar dosage regimens are suitable for the treatment and/or prophylaxis of hyperlipidaemia in non-human mammals.

The dosages regimens for the treatment of hypertension, cardiovascular disease and eating disorders will generally be those mentioned above in relation to hyperglycaemia.

In a further aspect the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of hyperglycaemia. The present invention also provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of hyperlipidaemia, hypertension, cardiovascular disease or certain eating disorders.

No toxicological effects have been established for a compound of formula (I) or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, in the abovementioned dosage ranges.

The following Procedures and Examples illustrate the invention but do not limit it in any way. Example 1 5)-3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2-methoxy- ethoxy)propanoic acid

Figure imgf000014_0001

A solution of [2S, N(lS)]-3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]- phenyl]-2-(2-methoxyethoxy)-N-(2-hydroxy-l-phenyledιyl)propanamide (1.846 g) in a mixture of 1M sulphuric acid (45 mL) and dioxan/water (1:1, 150 mL) was heated at 90°C for 56 hours and then the pH of the mixture was adjusted to pH 3 by addition of aqueous sodium hydrogen carbonate. The mixture was extracted with ethyl acetate and the organic extracts washed with water, brine, dried (MgSO4) and evaporated to give an oil. Purification by chromatography on silica gel using a gradient of 1-5% metiianol in dichloromethane as eluent gave a foam of 88% e.e. (by HPLC). The product was reacted with 5 -α-methylbenzylamine in acetone, and the resulting salt recrystallised several times from ethyl acetate-hexane before being dissolved in water, acidified with dilute hydrochloric acid and extracted with ethyl acetate which was dried with MgSO Evaporation of the ethyl acetate solution afforded enantiomerically enriched title compound; [α]D 25 -28° (c=0.625, CHCI3); e.e 94% (by HPLC); [Found M+ 414.1791. C22H26N2O6 requires M+ 414.1791]; >H NMR spectrum identical with that described in Example 5.

Example 2

(S)-3-[4-[2-[N.(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2 2,2- trifluoroethoxy)propanoic acid by hydrolysis of amide

Figure imgf000014_0002

[2S, N(lS)]-3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2,2,2- trifluoroethoxy)-N-(2-hydroxy-l-phenylethyl)propanamide (from Procedure 3) was hydrolysed by an analogous procedure to that described in Example 1. Purification by chromatography on silica gel using a gradient of 0-5% methanol in dichloromethane as eluent gave the title compound, mp 116-7°C, after trituration with diethyl ether-hexane; [α]D 25 -24.6° (c=0.24, CHCI3); e.e. 95% (by HPLC). [Found C, 57.9; H, 4.7; N, 6.8%; M+ 438.1403. C21H21F3N2O5 requires C, 57.5; H, 4.8; N, 6.4%; M+ 438.1403]; δH (DMSO-dg) 2.96 (2H,m), 3.22 (3H,s), 3.88 (2H,m), 3.95-4.18 (2H,m), 4.27 (3H,m), 6.8-7.37 (8H,m) and 12.9 (lH,br s, exchanges with D2O).

Example 3 S>-3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl-2-(2A2- trifluoroethoxy)propanoic Acid, by Direct Hydrolysis of the Imide

Figure imgf000015_0001

Aqueous sodium hydroxide solution (2.5M, 65 mL, 0.163 mol, 2.3 eq) was added to a stirred solution of [3(25), 45]-3-[3-[4-[2-[N-(2-benzoxazolyl)-N- methylamino]ethoxy]phenyl]-2-(2,2,2-trifluoroethoxy)propanoyl]-4- benzyloxazolidin-2-one (from Procedure 10)(42.5 g, 0.071 mol) in THF (500 mL) and water (125 mL). The mixture was stirred for 20 minutes, d e reaction was diluted with water (1 L) and extracted with dichloromethane (3 x 700 mL). These dichloromethane solutions were evaporated and the residue purified by chromatography on silica gel using 5% methanol in dichloromethane as eluent to afford 5 -4-benzyloxazolidin-2-one. The original aqueous solution was acidified to pH 3.5 wim dilute hydrochloric acid and re-extracted with dichloromeUiane (3 x 700 mL). The dichloromethane solutions from the acid extraction were dried (MgSO4) and evaporated to give a solid. This was recrystallised from dichloromethane-diethyl ether to afford the title compound, mp 119.5-120.5°C. [a]D^ = -31° (c = 2.50, CHC13); e.e. 99.6% (by HPLC); [Found C, 57.7; H, 4.7; N, 6.25%; M+ (El) 438.1412. C21H21F3N2O5 requires C, 57.5; H, 4.8; N, 6.4%; M+ 438.1403]; δH (CDCI3) 3.05 (IH, dd), 3.13 (IH, dd), 3.31 (3H, s), 3.72 (IH, m), 3.89 (2H, ), 4.04- 4.14 (3H, m), 4.21 (IH, dd), 6.78 (2H, d), 7.03-7.40 (6H, m) and 11.20 (IH, br, exchanges with D2O); δp (DMSO-dg) = -72.7 (3F, t, V^p 9.3 Hz, CF3).

Example 4 5 -3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl-2-(2^,2-tri- fluoroethoxy)propanoic Acid by Hydrolysis of Methyl Ester

Figure imgf000015_0002

A mixture of (Sj-methyl 3-[4-[2-[N-(2-benzoxazolyl)-N- methylamino]ethoxy]phenyl]-2-(2,2,2-trifluoroethoxy)propanoate (1.256 g, 2.8 x 10"3 mol), aqueous hydrochloric acid (2.0M, 50 mL) and dioxan (50 mL) was heated at reflux for 7 hours, cooled and concentrated in vacuo. The residue was suspended in brine (200 mL) and extracted with ethyl acetate (3 x 300 mL). The combined ediyl acetate solutions were dried (MgSO4) and evaporated to afford a waxy solid. This solid was triturated with hexane, filtered and dried under vacuum at 65°C to afford the desired product, mp 113-5°C. [αJo25 = -32° (c = 1.02, CHC13); e.e. 99.4% (by HPLC); [Found C, 57.25; H, 4.8; N, 6.3%. C21H21F3N2θ5 requires C, 57.5; H, 4.8; N, 6.4%]. The lU NMR spectrum of this material was identical to that produced in Example 3.

Example 5 S)-3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl-2-(2- methoxyethoxy)propanoic Acid

Figure imgf000016_0001

(S)-Methyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2- methoxyethoxy)propanoate was hydrolysed in a manner analogous to that described for Example 4. The crude reaction mixture was chromatographed on silica gel using 5% methanol in dichloromethane as eluent to afford the title compound, a gum. [α]D 25 = -27° (c = 0.73, CHCI3); e.e. 99.8% (by HPLC); [Found M+ (El) 414.1779. C22H26N2O6 requires M+ 414.1791]; δH (CDCI3) 2.90 (IH, dd), 3.15 (IH, dd), 3.33 (3H, s), 3.37 (3H, s), 3.40-3.70 (4H, m), 3.93 (2H, t), 4.05 (IH, dd), 4.21 (2H, t), 6.81 (2H, d) and 6.95-7.40 (6H,m).

Procedure 1

(±)-3-[4-[2-[N-(2-BenzoxazolyI)-N-methyiamino]ethoxy]phenyl]-2-(2- methoxyethoxy]propanoic acid

Figure imgf000017_0001

A mixture of methyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2- (2-methoxyethoxy)propanoate (1.08 g, Int. Patent Appl., Publication No. WO 9401420) and sodium hydroxide (253 mg) in methanol: water (1:1, 10 mL) was heated under reflux for 2 hours. After evaporation of the resultant mixture in vacuo, the residue was diluted with water, acidified to pH 5 with 2M hydrochloric acid and then extracted widi emyl acetate. Washing of die ediyl acetate extracts witii water and drying (MgSO ) and evaporation gave the title compound as an oil which crystallised on trituration with diethyl ether/hexane. [Found C, 63.8; H, 6.5; N, 7.0%; M+ 414.1791. C22H26N2O6 requires C, 63.8; H, 6.3; N, 6.8%; M+ 414.1791]; δH (CDC13) 2.91 (lH,dd), 3.15 (lH,dd), 3.34 (3H,s), 3.38 (3H,s), 3.41-3.69 (4H,m), 3.93 (2H,t), 4.05 (lH,dd), 4.21 (2H,t), 6.80 (2H,d) and 6.83-7.38 (6H m).

Procedure 2

(±)-3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2- methoxyethoxy)propanoyl chloride

Figure imgf000017_0002

Oxalyl chloride (92 mg) was added to (±)-3-[4-[2-[N-(2-benzoxazolyl)-N-methyl- amino]ethoxy]phenyl]-2-(2-methoxyethoxy)propanoic acid (100 mg) in dichloromethane (2 mL). The mixture was stirred at room temperature for 16 hours and evaporated to dryness to give die title compound as a gum which was used widiout further purification. Procedure 3

[25, N(LS)]-3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2- methoxyethoxy)-N-(2-hydroxy-l-phenylethyl)propanamide

Figure imgf000018_0001

(±)-3-[4-[2-[N-(2-Benzoxazolyl)-N-med ylamino]emoxy]phenyl]-2-(2-methoxy- ethoxy)propanoyl chloride was dissolved in dichloromethane (2 mL) and a mixture of 5)-2-phenylglycinol (33 mg) and dry triediylamine (37 mg) in dichloromethane (1 mL) added. After stirring for 5 minutes water was added and the mixture extracted witii dichlorometiiane. The organic extracts were washed with water, brine, dried (MgSO4) and evaporated. The residue was chromatographed on silica gel using a gradient of 10-50% acetone in hexane as eluent to afford firstly [2R, N(15)]-3-[4-[2- [N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2-methoxyethoxy)-N-(2- hydroxy- l-phenyledιyl)propanamide followed by the desired [25, N(15)]- propanamide title compound as a foam. [α]r>25 -33° (c=l.l, CHCI3); 92.6% d.e. (by HPLC); [Found M+ 533.2526. CSQ^S^OS requires M+ 533.2526]; δH (CDCI3) 2.81 (lH,dd), 3.07 (lH,dd), 3.35 (3H,s), 3.36 (3H,s), 3.48-3.58 (2H,m), 3.52-3.62 (2H,m), 3.71 (lH,dd), 3.82 (lH,dd), 3.94 (lH,dd), 3.93 (2H,t), 4.22 (3H,t), 5.05 (lH,dt), 6.75-7.35 (13H,complex), 7.54 (lH,br, exchanges with D2O).

Procedure 4

(±)-3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2^,2- trifluoroethoxy)propanoic acid

Figure imgf000018_0002

Methyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2,2,2- trifluoroethoxy)propanoate (Int. Patent Appi, Publication No. WO 9401420) was hydrolysed by an analogous procedure to that described in Procedure 1 to give the title compound as a solid, mp 116-117°C; [Found C, 57.4; H, 4.9; N, 6.4%. C21H2ιF3N2O5 requires C, 57.5; H, 4.8; N, 6.4%]; δH (CDC13) 3.03-3.17 (2H,m), 3.29 (3H,s), 3.73-3.83 (lH,m), 3.85 (2H,m), 4.02 (2H,m), 4.04-4.30 (2H,m) and 6.74-7.40 (8H m). Procedure 5

(±)-3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2Λ2- trifluoroethoxy)propanoyl chloride

Figure imgf000019_0001

Oxalyl chloride (1.1 mL) was added to a solution of (±)-3-[4-[2-[N-(2-benzoxazolyl)- N-methylamino]ethoxy]phenyl]-2-(2,2^-trifluoroethoxy)propanoic acid (1.72 g) in dry benzene (30 mL). The mixture was heated at reflux for 2 hours, cooled and evaporated to dryness to give the title compound as a gum which was used widiout further purification.

Procedure 6 [2S, N(lS)]-3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2,2,2- trifϊuoroethoxy)-N-(2-hydroxy-l-phenylethyl)propanamide

Figure imgf000019_0002

(±)-3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2,2,2- trifluoroethoxy)propanoyl chloride was reacted with (5 -2-phenylglycinol by an analogous procedure to that described in Procedure 3. Chromatography on silica gel using a gradient of 10-70% ethyl acetate in hexane as eluent afforded firstly [2R, N(15)]-3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2,2,2- trifluoroethoxy)-N-(2-hydroxy-l-phenylethyl)propanamide followed by the desired [25, N(15)]-propanamide title compound as a foam; [α]D 25 +14° (c=0.5, MeOH); 99% d.e. (by HPLC); [Found M+ 557.2136. C^r^^Os requires M+ 557.2138]; δH (CDC13) 2.35 (lH,br, exchanges with D2O), 2.91 (lH,dd), 3.13 (lH,dd), 3.36 (3H,s), 3.70-3.87 (2H,m), 3.84 (2H,d), 3.95 (2H,t), 4.12 (lH,dd),4.22 (2H,t), 5.01 (lH,m), 6.75 (2H,d), 6.97 (lH,br s, exchanges with D2O) and 7.01-7.36 (HH,complex). Procedure 7 (2,2,2-Trifluoroethoxy)ethanoyl Chloride

Figure imgf000020_0001

A solution of oxalyl chloride (20 mL, 0.23 mol, 1.15 eq) in dry dichloromethane (50 mL) was added dropwise at room temperature, widi stirring, to a solution of (2,2,2- trifluoroed oxy)ethanoic acid (Int. Patent Appl., Publication No. WO 87/07270, 31.6 g, 0.2 mol) and N,N-dimethylformamide (5 drops) in dry dichlorometiiane (400 mL). The mixture was stirred for an additional hour, tiien heated under reflux for 2 hours, cooled and d e bulk of d e solvent removed by distillation (bp 40-45°C 760 mm Hg). The residue was transferred to a Claisen distillation flask and the remaining solvent and oxalyl chloride removed by distillation (bp 45-60°C/760 mm Hg). Vacuum distillation of the residue then afforded the product, bp 50-55 25-32 mm Hg. δH (CDC13) 4.00 (2H, q, 3JHF 8.3) and 4.57 (2H, s).

Procedure 8 (45)-4-Benzyl-3-[2-(2,2,2-trifluoroethoxy)ethanoyl]oxazoUdin-2-one

Figure imgf000020_0002

(45)-4-Benzyloxazolidine-2-one (5.21 g, 0.029 mol) was dissolved in dry THF

(60 mL) and cooled to -70°C under argon. π-Butyllithium (18.4 mL, 1.6 M solution in hexane, 1.1 eq) was added over 10 minutes and the resulting mixture stirred at -70° C for 20 minutes. A solution of (2,2,2-trifluoroetiιoxy)ethanoyl chloride (5.19 g, 1 eq) in dry THF (60 mL) was added over 10 minutes, the mixture stirred at -70°C for a further 30 minutes then allowed to warm to room temperature overnight. The reaction was quenched by addition of brine (20 mL) and concentrated in vacuo. The residue was diluted with brine (300 mL) and extracted with ethyl acetate (3 x 300 mL). The combined organic extracts were dried (MgSO4), evaporated and the residue chromatographed on silica gel with dichloromethane as eluent to give the product as an oil. [α]D 25 = +48° (c = 2.55, CHCI3); e.e. 100% (by HPLC); [Found (CI, Ammonia) MH+ 318.0934. C14H14NO4F3 requires MH+ 318.0953]; δH (CDCI3) 2.82 (IH, dd), 3.34 (IH, dd), 4.02 (2H, q, HF 8-6), 4.30 (2H, m), 4.69 (IH, m), 4.84 (2H, s) and 7.15-7.40 (5H, m); δp (CDCI3) = -74.8 (3F, t, 3yw 8.6, CF3). Procedure 9

[3(2S, 3R), 4S]-3-[3-[4-[2-[N.(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl].3- hydroxy-2-(2,2,2-trifluoroethoxy)propanoyl]-4-benzyloxazolidin-2-one

Figure imgf000021_0001

(45)-4-Benzyl-3-[2-(2^,2-trifluoroethoxy)ethanoyl]oxazolidin-2-one (31.7 g, 0.1 mol) was dissolved in dry dichloromethane (300 mL) under argon and cooled to - 78°C (internal temperature of solution), using liquid nitrogen/acetone as the cooling medium. Triediylamine (16.72 mL, 1.2 eq) was added, followed by the slow addition, over approximately 10 minutes, of di-π-butylboron triflate (Aldrich Chemical Company, 1.0M solution in dichloromethane, 110 mL, 1.1 eq) such that die reaction temperature was maintained below -70°C. The mixture was stirred at -78°C for 50 minutes, dien d e cooling bath was replaced with an ice batii and the mixture stirred at 0°C for an additional 50 minutes before being recooled to -78°C. A solution of 4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]benzaldehyde (29.6 g, 1.0 eq) in dry dichloromethane (220 mL), precooled to -50°C, was added over ca. 12 minutes, such diat the reaction temperature was maintained below -70°C. The resulting mixture was stirred at -78°C for 30 minutes, then warmed from -78°C to 0°C over 60 minutes along a linear gradient (warming rate ~ 1.3°C.min-1) and stirred at 0°C for a further 75 minutes. The reaction mixture was poured into a quenching solution of methanol (500 mL), pH 7 phosphate buffer (250 mL) and hydrogen peroxide (27.5% w/v, 110 mL) and stirred vigourously for 30 minutes. Water (4 L) was added, the layers were separated and the aqueous layer was extracted with dichloromethane (3 x 1 L). The dichloromethane solutions were recombined with the original dichloromethane layer from the reaction mixture and this organic solution was dien washed with water (2 L) and brine (2 L), dried (MgSO4) and evaporated to afford a foam. !H NMR of this crude reaction mixture suggested a mixture of the desired aldol product (3 diastereoisomers, comprising 95% major diastereoisomer) and starting materials. The crude mixture was chromatographed on silica gel using a gradient elution comprising 15% ethyl acetate in dichloromethane initially (until die desired product began to elute) and rising to 50% ethyl acetate in dichloromethane to complete the elution of the desired product. Unreacted i ide and aldehyde were recovered from the early fractions, followed by a quantity of impure product and then the title compound (comprising 2 diastereoisomers, ratio 97.8:2.2 by NMR). [α]rj25 = +45° (c = 2.82, CHC13). [Found (El) M+ 613.2042. C31H3oF3N3O7 requires M+ 613.2036]; δH (CDCI3, only major diastercoisomer is recorded) 2.75 (IH, dd), 2.90 (IH, d, exchanges with D2O), 3.25 (IH, dd), 3.34 (3H, s), 3.80-4.00 (5H, m), 4.07 (IH, dd), 4.24 (2H, t), 4.45 (IH, m), 4.99 (IH, apparent t), 5.48 (IH, d), 6.85 (2H, d) and 6.95-7.40 (1 IH, m); δ> (CDCI3) = -74.7 (3F, t, HP 8.5, CF3). The minor diastereoisomer in the purified product was identified as die [3(25, 35), 45]-diastereo- isomer.

Procedure 10 Preparation of [3(25), 4S]-3-[3-[4-[2-[N-(2-Benzoxazolyl)-N- methylamino]ethoxy]phenyI]-2-(2,2,2-trifluoroethoxy)propaπoyl]-4- benzyloxazolidin-2-one by Dehydroxylation

Figure imgf000022_0001

Triediylsilane (120 mL, 0.75 mol) was added over 5 minutes to a stirred, ice cooled solution of [3(25, 3Λ), 45]-3-[3-[4-[2-[N-(2-benzoxazolyl)-N- medιylamino]ethoxy]phenyl]-3-hydroxy-2-(2^,2-trifluoroethoxy)propanoyl]-4- benzyloxazolidin-2-one (46.23 g, 7.5 x 10"2 mol) in trifluoroacetic acid (650 mL). The mixture was stirred at 0°C for 1 hour, then at room temperature for a further 60 hours. The bulk of die solvent and residual triediylsilane was removed by rotary evaporation, firstly at 40 mm Hg and finally at -5 mm Hg. The residue was dissolved in dichloromethane (800 mL) and water (800 mL), then stirred vigorously during the cautious addition of solid sodium bicarbonate (~29 g) (frothing !) until die pH of the aqueous layer was pH 7. The layers were separated and the aqueous layer was extracted widi dichloromediane (800 mL). The combined dichloromethane layers were washed with water (600 mL), dried (MgSO4) and evaporated. The residue was triturated wid hot hexane and the resulting solid collected by filtration. Recrystallisation from diethyl ether-hexane afforded the title compound, mp 107-109°C, a single diastereoisomer by l NMR spectroscopy. [α]rj25 = +38° (c = 1.51, CHCI3); [Found C, 62.1; H, 4.9; N, 7.2%; M+ (El) 597.2089.

C31H30N3O6F3 requires C, 62.3; H, 5.1; N, 7.0%; M+ 597.2087]; δH (CDCI3) 2.82 (IH, dd), 2.96 (IH, dd), 3.04 (IH, dd), 3.32 (IH, dd), 3.34 (3H, s), 3.70 (IH, m), 3.88 (IH, m), 3.94 (2H, t), 4.12 (IH, m), 4.18 (IH, m), 4.25 (2H, t), 4.57 (IH, m), 5.34 (IH, dd), 6.82 (2H, d) and 7.00-7.35 (1 IH, m); δF (CDCI3) = -74.8 (3F, t, ^ 8.6, CF3). Procedure 11

Preparation of [3(2S), 4S]-3-[3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]- ethoxy]phenyl]-2-(2,2,2-trifluoroethoxy)propanoyl]-4-benzyloxazoIidin-2-one by

Diastereoisomer Separation

Figure imgf000023_0001

(5 -4-Benzyloxazolidin-2-one (0.291 g, 1.64 x 10"3 mol) was dissolved in dry THF (10 mL) and the resulting solution cooled to -70°C under argon. n-Butyl lithium (1.6M in hexane, 1.03 mL, 1.64 x 10-3 mol) was added and the mixture was stirred at -70°C for 10 minutes prior to the addition of a solution of (±)-3-[4-[2-[N-(2- benzoxazolyl)-N-memylamino]edιoxy]phenyl]-2-(2,2,2-trifluoroedιoxy)propanoyl chloride (prepared from 0.36 g of d e acid by Procedure 5, above) in dry THF (15 mL). The reaction was stirred and allowed to warm to room temperature overnight before being diluted widi water (200 mL) and extracted with ethyl acetate (2 x 200 mL). The combined ethyl acetate layers were washed widi water (200 mL) and brine (200 mL), dried (MgSO4) and evaporated to give a brown gum. This was chromatographed on silica gel using a gradient of 35% to 50% ediyl acetate in hexane as eluent to afford firsdy the (R, 5 -diastereoisomer, followed by d e tide compound, a foam. This material was spectroscopically identical with that prepared by the aldol route (Procedure 10).

Procedure 12

(S)-MethyI 3-[4-[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2^,2- trifluoroethoxy)propanoate

Figure imgf000023_0002

A solution of sodium medioxide [prepared from sodium hydride (60% dispersion in mineral oil, 138 mg, 3.41 x 10-3 mol) dissolved in dry methanol (3.5 mL)] was added to an ice cooled and stirred suspension of [3(25), 45]-3-[3-[4-[2-[N-(2- benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2,2,2-trifluoroethoxy)propanoyl]- 4-benzyloxazolidin-2-one (1.879 g, 3.1 x 10'3 mol) in dry methanol (100 mL). The mixture was stirred at 0°C for a total of 20 minutes, then the reaction was quenched by die addition of dilute aqueous hydrochloric acid (2.0M, 1.75 mL) and concentrated in vacua. The residue was suspended in water (100 mL), extracted with ethyl acetate (3 x 200 mL) and the combined ediyl acetate solutions washed widi brine (500 mL), dried (MgSO4) and evaporated. The resulting gum was chromatographed on silica gel using 4% ethyl acetate in dichloromethane as eluent to afford die product as a clear gum. [a]O^ = 7° (c = 1.24, CHCI3); [Found (El) M+ 452.1561. C22H23N2O5F3 requires M+ 452.1559]; e.e. 100% (by HPLC); δH (CDCI3) 3.02 (2H, m), 3.34 (3H, s), 3.65 (IH, m), 3.72 (3H, s), 3.94 (2H, t), 4.00 (IH, m), 4.13 (IH, dd), 4.24 (2H, t), 6.80 (2H, d) and 6.96-7.40 (6H, m).

Procedure 13 (45)-4-Benzyl-3-[2-(2-methoxyethoxy)ethanoyl]oxazolidin-2-one

Figure imgf000024_0001

The tide compound was prepared from 2-(2-metiιoxyethoxy)etiιanoyl chloride by a method analogous to tiiat described in Procedure 8. Chromatography on silica gel using a gradient of 70-80% diethyl ether in hexane as eluent afforded the product as a gum. [αto25 = +54° (c = 2.70, CHC13); [Found (El) M+ 293.1263. C15H19NO5 requires M+ 293.1264]; δH (CDCI3) 2.81 (IH, dd), 3.33 (IH, dd), 3.41 (3H, s), 3.63 (2H, t), 3.78 (2H, t), 4.25 (2H, m), 4.70 (IH, m), 4.74 (IH, d), 4.76 (IH, d) and 7.10- 7.40 (5H, m).

Procedure 14

[3(2S, 3Λ), 4S]-3-[3-[4.[2-[N-(2-Benzoxazolyl)-N-methylamino]ethoxy]phenyl]-3- hydroxy-2-(2-methoxyethoxy)propanoyl]-4-benzyloxazolidin-2-one

Figure imgf000024_0002

The tide compound was prepared from (45)-4-benzyl-3-[2-(2- methoxyethoxy)ethanoyl]oxazolidin-2-one by a method analogous to that described in Procedure 9. The crude reaction mixture was chromatographed on silica gel using a gradient of 15-40% ethyl acetate in dichloromediane to afford die product as a gum (comprising 2 diastereoisomers, ratio >99:1 by !H NMR). [α]D 25 = +49° (c = 1.14, CHCI3). [Found (FAB, NOBA/Na) MH+ 590.2472. C32H35N3O8 requires MH+ 590.2502]; δy (CDCI3, only major diastereoisomer is recorded) 2.71 (IH, dd), 3.25 (IH, dd), 3.31 (3H, s), 3.35 (3H, s), 3.56 (2H, m), 3.72 (2H, m), 3.78 (IH, d, exchanges with D2O), 3.85-4.00 (4H, m), 4.22 (2H, t), 4.31 (IH, m), 4.89 (IH, dd), 5.42 (IH, d), 6.83 (2H, d) and 6.95-7.40 (1 IH, m); The minor diastereoisomer in the purified product was identified as die [3(25, 35), 45]-diastereoisomer.

Procedure 15

[3(25), 4S]-3-[3-[4-[2-[N-(2-Benzoxazolyl)-N-methyiamino]ethoxy]phenyl]-2-(2- methoxyethoxy)propanoyl]-4-benzyloxazolidin-2-one

Figure imgf000025_0001

[3(25, 3R), 45]-3-[3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-3- hydroxy-2-(2-medιoxyethoxy)propanoyl]-4-benzyloxazolidin-2-one (0.561 g) was reacted wid triediylsilane for 6.25 hrs in a manner similar to tiiat described for Procedure 10. The reaction mixture was diluted widi water (200 mL) and dichloromethane (200 mL) and solid sodium bicarbonate was added cautiously until die aqueous layer showed pH 6.5. The layers were separated, the aqueous layer was extracted widi dichloromediane (2 x 300 mL) and the combined dichloromediane solutions were washed widi brine (400 mL), dried (MgSO4) and evaporated. The residue was chromatographed on silica gel using 35% ethyl acetate in dichloromediane as eluent to afford d e tide compound, a gum, as a single diastereoisomer by *H NMR. [αJo25 = +45° (c = 1.39, CHCI3); [Found M+ (El) 573.2473. C32H35N3O7 requires M+ 573.2475]; δH (CDCI3) 2.76 (IH, dd), 2.94 (2H, m), 3.30 (3H, s), 3.33 (4H, m), 3.40-3.70 (4H, m), 3.93 (2H, t), 4.00 (IH, dd), 4.12 (IH, dd), 4.22 (2H, t), 4.52 (IH, m), 5.31 (IH, dd), 6.79 (2H, d) and 6.90-7.40 (l lH, m).

Procedure 16

(5)-Methyl 3-[4-[2-[N-(2-BenzoxazolyI)-N-methylamino]ethoxy]phenyl]-2-(2- methoxyethoxy)propanoate

Figure imgf000025_0002
[3(25), 45]-3-[3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2- medιoxyed oxy)propanoyl]-4-benzyloxazolidin-2-one was reacted widi sodium medioxide in a manner analogous to tiiat described in Procedure 12. The crude reaction mixture was chromatographed on silica gel using 20% isohexane in died yl edier as eluent to afford the title compound, a gum. [COD25 = -12° (c = 1.26, CHCI3); [Found (El) M+ 428.1974. C23H28N2O6 requires M+ 428.1948]; e.e. >99.8% (by HPLC); δH (CDCI3) 2.95 (2H, m), 3.29 (3H, s), 3.34 (3H, s), 3.35 (3H, m), 3.69 (4H, m), 3.93 (2H, t), 4.05 (IH, dd), 4.23 (2H, t) and 6.75-7.40 (8H, m).

DEMONSTRATION OF EFFICACY OF COMPOUNDS

Obese Mice, Oral Glucose Tolerance Test

C57M1/6 obese (ob/ob) mice were fed on powdered oxoid diet. After at least one week, the mice continued on a powdered oxoid diet or were fed powered oxoid diet containing die test compound. After 8 days on the supplemented diet all of die mice were fasted for 5 hours prior to receiving an oral load of glucose (3g/kg). Blood samples for glucose analysis were taken 0, 45, 90 and 135 minutes after glucose administration and d e results appear below as the percentage reduction in area under die blood glucose curve where test compound treated groups are compared with die control group. 8 mice were used for each treatment.

Table

% Reduction in

Level in diet area under blood imple (μmol. kg'1 of diet) glucose curve

1 0.3 24

2 0.3 24

Effects on packed red cell volume and heart weight:

These were determined after repeat oral administration of compound (once daily at a dose of 3 μmol kg body wt for 14 days, by gavage) to female Sprague- Dawley rats for 14 days. Changes shown are percentage changes from control. Statistical comparisons were made by Student t test for non-paired data; *p<0.05, ***p<0.001 versus controls. No effect no significant difference from control group. Results were obtained from 8 rats per treatment group.

Compound Heart weight Packed cell volume

Example (% increase) (% reduction)

1 No effect No effect

2 No effect No effect

Claims

Claims:
1. A compound of formula (I) :
Figure imgf000028_0001
or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein R° represents 2-benzoxazolyl or 2-pyridyl and R* represents CH2OCH3 or CF3.
2. A compound according to claim 1, wherein R° represents 2-benzoxazolyl.
3. A compound according to claim 1, wherein R represents CF3
4. A compound according to claim 1 being:
5 -3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2-methoxy- edιoxy)propanoic acid;or
(5)-3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]-2-(2,2,2- trifluoroethoxy)propanoic acid; or a pharmaceutically acceptable salt diereof, and/or a pharmaceutically acceptable solvate diereof.
5. A compound of formula (I) according to claim 1, when present in admixture with less than 50% w/w of its racemic isomer.
6. A compound of formula (I) according to claim 1, when 90-100% optically pure.
7. A compound of formula (I) according to claim 1, in optically pure form.
8. A pharmaceutical composition comprising a compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier therefor.
9. A method for die treatment and/or prophylaxis of hyperglycaemia or hyperlipidaemia in a human or non-human mammal which comprises administering an effective, non-toxic, amount of a compound of the general formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate diereof, to a hyperglycaemic human or non-human mammal in need thereof.
PCT/GB1995/001323 1994-07-29 1995-06-07 Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes WO1996004261A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GB9415330A GB9415330D0 (en) 1994-07-29 1994-07-29 Novel compounds
GB9425599A GB9425599D0 (en) 1994-12-19 1994-12-19 Novel compounds
GB9509923A GB9509923D0 (en) 1995-05-17 1995-05-17 Novel compounds
GB9509923.0 1995-06-07
GB9425599.9 1995-06-07
GB9415330.1 1995-06-07

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
DZ950094A DZ1916A1 (en) 1994-07-29 1995-07-26 Compounds and new pharmaceutical compositions containing them.
IL11475995A IL114759A (en) 1994-07-29 1995-07-27 Benzoxazole derivatives and pharmaceutical compositions containing them
MA23972A MA23632A1 (en) 1994-07-29 1995-07-27 Process for the preparation of compounds and new pharmaceutical compositions containing them
CZ25497A CZ9700254A3 (en) 1994-07-29 1995-07-28 Benzoxazoles and pyridine derivatives usable for treating type ii diabetes
AU3382695A AU697545B2 (en) 1994-07-29 1995-07-28 Benzoxazoles and pyridine derivatives useful in the treatment of the ty pe II diabetes
PL31876695A PL318766A1 (en) 1994-07-29 1995-07-28 Derivatives of benzoxazoles and pyridines useful in treating diabetes of type ii
AP9700918A AP776A (en) 1994-07-29 1995-07-28 Benzoxazoles and pyridine derivatives useful in the treatment of the type Ii diabetes.
EP19950930436 EP0772605A1 (en) 1994-07-29 1995-07-28 Benzoxazoles and pyridine derivatives useful in the treatment of the type ii diabetes
MX9700763A MX9700763A (en) 1994-07-29 1995-07-28 Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes.
CN 95195163 CN1158123A (en) 1994-07-29 1995-07-28 Benzoxazoles and pyridine derivatives useful in the treatment of the type II diabetes
PCT/EP1995/003038 WO1996004260A1 (en) 1994-07-29 1995-07-28 Benzoxazoles and pyridine derivatives useful in the treatment of the type ii diabetes
JP50619496A JPH10503508A (en) 1994-07-29 1995-07-28 Useful benzoxazole and pyridine derivatives in the treatment of Ii diabetes mellitus
BR9508468A BR9508468A (en) 1994-07-29 1995-07-28 Compound process for preparing the same composition pharmaceutical methods for the treatment and / or hyperglycemia prophylaxis in a human or non-human mammal and for treatment of hyperlipidemia, hypertension, cardiovascular disease, certain eating disorders, the treatment and / or prophylaxis of renal disease prevention reversing the stabilization or retardation of the progression of microalbuminuria in a human or non-human mammal use of the compound and intermediate compound
NZ29212595A NZ292125A (en) 1994-07-29 1995-07-28 Benzoxazole and pyridine substituted phenyl carboxylic acid derivatives; medicaments
HU9700264A HUT76637A (en) 1994-07-29 1995-07-28 Bezoxazoles and pyridine derivatives, pharmaceutical compositions containing them, process for producing them and their use and the intermediates of the compounds
TR9500916A TR199500916A2 (en) 1994-07-29 1995-07-28 The novel compounds to be used in medicine for.
NO970373A NO307827B1 (en) 1994-07-29 1997-01-28 Benzoxazol- and pyridine derivatives, their use and pharmaceutical compositions containing them
FI970357A FI970357A (en) 1994-07-29 1997-01-28 the treatment of type II diabetes and pyridine derivatives useful bensoksatsoli-
BG10118097A BG101180A (en) 1994-07-29 1997-01-29 Benzoxazoles and pyridine derivatives useful in the treatment of the type ii diabetes
OA60957A OA10470A (en) 1994-07-29 1997-01-29 Benzoxazoles and pyridine derivates useful in the treatment of the type ii diabetes
IL12552598A IL125525D0 (en) 1994-07-29 1998-07-27 Hydroxyalkylamine derivatives
AU1006199A AU1006199A (en) 1994-07-29 1999-01-08 Benzoxazoles and pyridine derivatives useful in the treatment of the Type II diabetes

Publications (1)

Publication Number Publication Date
WO1996004261A1 true true WO1996004261A1 (en) 1996-02-15

Family

ID=27267309

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB1995/001323 WO1996004261A1 (en) 1994-07-29 1995-06-07 Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
PCT/EP1995/003038 WO1996004260A1 (en) 1994-07-29 1995-07-28 Benzoxazoles and pyridine derivatives useful in the treatment of the type ii diabetes

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/003038 WO1996004260A1 (en) 1994-07-29 1995-07-28 Benzoxazoles and pyridine derivatives useful in the treatment of the type ii diabetes

Country Status (4)

Country Link
EP (1) EP0772605A1 (en)
CA (1) CA2196079A1 (en)
FI (1) FI970357A (en)
WO (2) WO1996004261A1 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997025042A1 (en) * 1996-01-09 1997-07-17 Smithkline Beecham P.L.C. Use of an agonist of ppar-alpha and ppar-gamma for the treatment of syndrom x
WO2000023416A1 (en) * 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000023425A1 (en) * 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000023417A1 (en) * 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000023415A1 (en) * 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000023451A1 (en) * 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000023445A1 (en) * 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000063153A1 (en) * 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
WO2000063189A1 (en) * 1999-04-16 2000-10-26 Novo Nordisk A/S Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate
WO2000063209A1 (en) * 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
WO2000063190A1 (en) * 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
US6214820B1 (en) 1998-10-21 2001-04-10 Novo Nordisk A/S Compounds, their preparation and use
US6248781B1 (en) 1998-10-21 2001-06-19 Novo Nordisk A/S Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR)
US6274608B1 (en) 1999-04-20 2001-08-14 Novo Nordisk A/S Compounds, their preparation and use
US6300339B1 (en) 1998-10-21 2001-10-09 Novo Nordisk A/S Compounds, their preparation and use
US6365586B1 (en) 1998-10-21 2002-04-02 Novo Nordisk A/S Compounds, their preparation and use
US6369055B1 (en) 1999-04-20 2002-04-09 Novo Nordisk A/S Compounds, their preparation and use
US6468996B1 (en) 1998-10-21 2002-10-22 Novo Nordisk A/S Substituted hetero-polycyclic compounds as PPARα and PPARγ activators
US6555577B1 (en) 2000-01-28 2003-04-29 Novo Nordisk A/S Compounds, their preparation and use
US6569901B2 (en) 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
US6939853B2 (en) 2001-12-29 2005-09-06 Novo Nordisk A/S Combined use of a GLP-1 compound and another drug for treating dyslipidemia
US6972294B1 (en) 1999-04-20 2005-12-06 Novo Nordisk, A/S Compounds, their preparation and use
US7015345B2 (en) 2002-02-21 2006-03-21 Asahi Kasei Pharma Corporation Propionic acid derivatives
US7041837B2 (en) 2001-07-26 2006-05-09 Cadilla Healthcare Limited Heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine
US7414128B2 (en) 1999-04-20 2008-08-19 Dr. Reddy's Laboratories, Limited Crystalline R-guanidines, Arginine or (L)-Arginine (2S)-2-Ethoxy-3-{4-[2-(10H -phenoxazin-10-yl)ethoxy]phenyl}propanoate
WO2012104869A1 (en) 2011-01-31 2012-08-09 Cadila Healthcare Limited Treatment for lipodystrophy
WO2015001573A1 (en) 2013-07-05 2015-01-08 Cadila Healthcare Limited Synergistic compositions
US9814697B2 (en) 2013-04-22 2017-11-14 Cadila Healthcare Limited Composition for nonalcoholic fatty liver disease (NAFLD)
US10098868B2 (en) 2013-07-25 2018-10-16 Cadila Healthcare Limited Formula comprising a hypolipidemic agent
US10112898B2 (en) 2013-09-06 2018-10-30 Cadila Healthcare Limited Process for the preparation of saroglitazar pharmaceutical salts

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000005224A (en) * 1996-04-04 2000-01-25 가와무라 요시부미 Phenylalkylcarboxylic acid derivatives
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
CN1280561A (en) 1997-10-02 2001-01-17 三共株式会社 Amidocarboxylic acid derivatives
JP2002507543A (en) * 1998-05-27 2002-03-12 ドクター・レディーズ・リサーチ・ファウンデーション Bicyclic compounds, pharmaceutical compositions containing the preparation and their
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
WO1999019313A1 (en) * 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
US6444816B1 (en) 1997-10-27 2002-09-03 Dr. Reddy's Research Foundation Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof
US6130214A (en) 1997-10-27 2000-10-10 Dr. Reddy's Research Foundation Benzothiazin and benzoxazin derivatives; their preparation and uses
US6265401B1 (en) 1997-10-27 2001-07-24 Reddy-Cheminor, Inc. Bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US6531596B1 (en) 1998-10-29 2003-03-11 Dr. Reddy's Laboratories Ltd. Process for the preparation of new antidiabetic agents
CA2346941A1 (en) * 1998-10-29 2000-05-11 Om Reddy Gaddam An improved process for the preparation of new antidiabetic agents
DK1206457T3 (en) 1999-08-27 2004-02-16 Lilly Co Eli Biaryl-oxa (thia) zolderivater and their use as modulators PPAP'ER
CN1396904A (en) * 2000-01-28 2003-02-12 诺沃挪第克公司 Novel compound, their preparation and use
US6509374B2 (en) 2000-04-17 2003-01-21 Novo Nordisk A/S Compounds, their preparation and use
US6908908B2 (en) 2000-05-12 2005-06-21 Ortho-Mcneil Pharmaceutical, Inc. Biologically active 4H-benzo [1,4] oxazin-3-ones
EP1280783A2 (en) * 2000-05-12 2003-02-05 Ortho-McNeil Pharmaceutical, Inc. Methods of treatment using benzoxazinones as peroxisome proliferator activated receptor gamma modulators
US7067530B2 (en) 2001-07-30 2006-06-27 Novo Nordisk A/S Compounds, their preparation and use
US6869967B2 (en) 2001-07-30 2005-03-22 Novo Nordisk A/S Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
US7220877B2 (en) 2001-10-17 2007-05-22 Novo Nordisk A/S Compounds, their preparation and use
US7816385B2 (en) 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
US6653334B1 (en) 2002-12-27 2003-11-25 Kowa Co., Ltd. Benzoxazole compound and pharmaceutical composition containing the same
EP2154131A4 (en) * 2007-04-26 2011-09-21 Pharmafrontier Co Ltd G protein-coupled receptor inhibitor and pharmaceutical product

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991019702A1 (en) * 1990-06-14 1991-12-26 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
WO1994001420A1 (en) * 1992-07-03 1994-01-20 Smithkline Beecham Plc Heterocyclic compounds as pharmaceutical

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991019702A1 (en) * 1990-06-14 1991-12-26 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
WO1994001420A1 (en) * 1992-07-03 1994-01-20 Smithkline Beecham Plc Heterocyclic compounds as pharmaceutical

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997025042A1 (en) * 1996-01-09 1997-07-17 Smithkline Beecham P.L.C. Use of an agonist of ppar-alpha and ppar-gamma for the treatment of syndrom x
US6166049A (en) * 1996-01-09 2000-12-26 Smithkline Beecham P.L.C. Use of an antagonist of PPARα and PPARγ for the treatment of syndrome X
US6602901B2 (en) 1998-10-21 2003-08-05 Novo Nordisk A/S Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR)
WO2000023417A1 (en) * 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000023415A1 (en) * 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000023451A1 (en) * 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000023425A1 (en) * 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
US6683111B2 (en) 1998-10-21 2004-01-27 Novo Nordisk A/S Compounds, their preparation and use
WO2000023445A1 (en) * 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
US6525086B2 (en) 1998-10-21 2003-02-25 Novo Nordisk A/S Compounds, their preparation and use
US6468996B1 (en) 1998-10-21 2002-10-22 Novo Nordisk A/S Substituted hetero-polycyclic compounds as PPARα and PPARγ activators
WO2000023416A1 (en) * 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
US6214820B1 (en) 1998-10-21 2001-04-10 Novo Nordisk A/S Compounds, their preparation and use
US6248781B1 (en) 1998-10-21 2001-06-19 Novo Nordisk A/S Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR)
US6407127B2 (en) 1998-10-21 2002-06-18 Novo Nordisk A/S Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR)
US6300339B1 (en) 1998-10-21 2001-10-09 Novo Nordisk A/S Compounds, their preparation and use
US6353018B1 (en) 1998-10-21 2002-03-05 Novo Nordisk A/S Compounds, their preparation and use
US6365586B1 (en) 1998-10-21 2002-04-02 Novo Nordisk A/S Compounds, their preparation and use
US6723731B2 (en) 1998-10-21 2004-04-20 Novo Nordisk A/S Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR)
US6703401B2 (en) 1998-10-21 2004-03-09 Novo Nordisk A/S Compounds, their preparation and use
WO2000063189A1 (en) * 1999-04-16 2000-10-26 Novo Nordisk A/S Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate
US6274608B1 (en) 1999-04-20 2001-08-14 Novo Nordisk A/S Compounds, their preparation and use
WO2000063209A1 (en) * 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
US7414128B2 (en) 1999-04-20 2008-08-19 Dr. Reddy's Laboratories, Limited Crystalline R-guanidines, Arginine or (L)-Arginine (2S)-2-Ethoxy-3-{4-[2-(10H -phenoxazin-10-yl)ethoxy]phenyl}propanoate
US6972294B1 (en) 1999-04-20 2005-12-06 Novo Nordisk, A/S Compounds, their preparation and use
WO2000063153A1 (en) * 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
WO2000063190A1 (en) * 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
US6369055B1 (en) 1999-04-20 2002-04-09 Novo Nordisk A/S Compounds, their preparation and use
US6555577B1 (en) 2000-01-28 2003-04-29 Novo Nordisk A/S Compounds, their preparation and use
US6569901B2 (en) 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
US6867218B2 (en) 2000-01-28 2005-03-15 Novo Nordisk A/S Compounds, their preparation and use
US7202213B2 (en) 2000-01-28 2007-04-10 Novo Nordisk A/S Combination therapy using a dual PPAR-α/PPAR-γ activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders
US8110598B2 (en) 2001-07-26 2012-02-07 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7041837B2 (en) 2001-07-26 2006-05-09 Cadilla Healthcare Limited Heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine
US7323491B2 (en) 2001-07-26 2008-01-29 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US8558009B2 (en) 2001-07-26 2013-10-15 Cadila Healthcare Limited Pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine
US6939853B2 (en) 2001-12-29 2005-09-06 Novo Nordisk A/S Combined use of a GLP-1 compound and another drug for treating dyslipidemia
US7015345B2 (en) 2002-02-21 2006-03-21 Asahi Kasei Pharma Corporation Propionic acid derivatives
WO2012104869A1 (en) 2011-01-31 2012-08-09 Cadila Healthcare Limited Treatment for lipodystrophy
US10017470B2 (en) 2011-01-31 2018-07-10 Cadila Healthcare Limited Treatment for lipodystrophy
EP3009136A1 (en) 2011-01-31 2016-04-20 Cadila Healthcare Limited Treatment for lipodystrophy
US9783495B2 (en) 2011-01-31 2017-10-10 Cadila Healthcare Limited Treatment for lipodystrophy
US9814697B2 (en) 2013-04-22 2017-11-14 Cadila Healthcare Limited Composition for nonalcoholic fatty liver disease (NAFLD)
US9656954B2 (en) 2013-07-05 2017-05-23 Cadila Healthcare Limited Synergistic compositions
EP3120845A1 (en) 2013-07-05 2017-01-25 Cadila Healthcare Limited Synergistic compositions
US9957230B2 (en) 2013-07-05 2018-05-01 Cadila Healthcare Limited Synergistic compositions
WO2015001573A1 (en) 2013-07-05 2015-01-08 Cadila Healthcare Limited Synergistic compositions
US10098868B2 (en) 2013-07-25 2018-10-16 Cadila Healthcare Limited Formula comprising a hypolipidemic agent
US10112898B2 (en) 2013-09-06 2018-10-30 Cadila Healthcare Limited Process for the preparation of saroglitazar pharmaceutical salts

Also Published As

Publication number Publication date Type
FI970357A0 (en) 1997-01-28 application
CA2196079A1 (en) 1996-02-15 application
FI970357D0 (en) grant
EP0772605A1 (en) 1997-05-14 application
WO1996004260A1 (en) 1996-02-15 application
FI970357A (en) 1997-03-26 application

Similar Documents

Publication Publication Date Title
US5948792A (en) Fluorine-containing 1,4-disubstituted piperidine derivatives
US5541197A (en) Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
US5451677A (en) Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
US4906657A (en) Bicyclo heptane and bicyclo octane substituted inhibitors of cholesterol synthesis
US5306726A (en) 3-aryl-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5741803A (en) Substituted thiazolidinedionle derivatives
US5688787A (en) Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
US5010090A (en) N-(butenyl substituted) azaheterocyclic carboxylic acids
US4950675A (en) Pyridine di-mevalono-lactones as inhibitors of cholesterol biosynthesis
US5698548A (en) Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5770615A (en) Catecholamine surrogates useful as β3 agonists
US5925656A (en) Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5232945A (en) 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US4521428A (en) Anorexigenic trifluoromethylphenyltetrahydropyridines and pharmaceutical compositions containing them
US6518290B1 (en) Substituted oxazoles and thiazoles derivatives as HPPAr alpha activators
US5889032A (en) Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5260445A (en) 2,4-thiazolidinediones
US5194443A (en) Compounds
US4918091A (en) Novel thiazolidinediones
US5502078A (en) Chemical compounds
US4309443A (en) Cinnamic acid derivatives, their preparation, and pharmaceutical compositions containing them
US5932601A (en) Oxazolidinedione derivatives, their production and use
US5106992A (en) 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US5521201A (en) Method for treatment of atherosclerosis
US5153210A (en) Compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): MG US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase in:

Ref country code: US

Ref document number: 1997 776499

Date of ref document: 19970428

Kind code of ref document: A

Format of ref document f/p: F